Bone Biologics Corporatio... (BBLG)
| Bid | 0.73 |
| Market Cap | 2.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.82M |
| EPS (ttm) | -1.46 |
| PE Ratio (ttm) | -0.57 |
| Forward PE | -0.5 |
| Analyst | n/a |
| Ask | 0.87 |
| Volume | 73,913 |
| Avg. Volume (20D) | 235,858 |
| Open | 0.85 |
| Previous Close | 0.89 |
| Day's Range | 0.83 - 0.90 |
| 52-Week Range | 0.80 - 4.25 |
| Beta | 0.82 |
About BBLG
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L...
7 months ago · businesswire.com
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross ProceedsBURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
12 months ago · businesswire.com
Bone Biologics Announces Closing of $2.0 Million Public OfferingBURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
12 months ago · businesswire.com
Bone Biologics Announces Pricing of $2.0 Million Public OfferingBURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
